Can MS patients safely switch to a gentler drug?
NCT ID NCT06529406
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether people with stable relapsing multiple sclerosis can safely switch from anti-CD20 therapies (like rituximab or ocrelizumab) to ozanimod (Zeposia), an oral pill. About 100 participants who have had no new MS activity for at least two years will be followed for new brain lesions and infections. The goal is to see if this de-escalation approach keeps the disease under control while reducing treatment burden.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ozanimod (Zeposia)
- What this could lead to
- If successful, this could offer a way for people with stable MS to switch from stronger anti-CD20 therapies to a potentially safer, oral medication.
- What could go wrong
- This is a small pilot study, so results may not apply to everyone. There is a risk of new MS activity or infections when switching treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
RECRUITINGLas Vegas, Nevada, 89106, United States
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.